Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways

Cisplatin is currently used to treat inoperable recurrent meningiomas, but its side effects and drug resistance limit its use. Metformin has recently been identified as a chemosensitizing agent. However, the combined treatment of cisplatin and metformin in high-grade meningiomas has not been reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Liemei, Cui, Jing, Wang, Herui, Medina, Rogelio, Zhang, Shilei, Zhang, Xiaohua, Zhuang, Zhengping, Lin, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851485/
https://www.ncbi.nlm.nih.gov/pubmed/33575476
http://dx.doi.org/10.1016/j.omto.2020.11.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851485/
https://www.ncbi.nlm.nih.gov/pubmed/33575476
http://dx.doi.org/10.1016/j.omto.2020.11.004

Ejemplares similares